compounded glp-1 vs non compounded Affordability and Safety: How Hims & Hers is Delivering a New Experience Through the Scale of Our Platform FDA restricts non-approved compounded GLP-1

Here's what we learned about midlife GLP-1 use in 2025.

Patients switch because of efficacy, tolerability, access, cost, insurance coverage, or newer options becoming available

insurance), a limited evaluation of long-term costs associated with either treatment modality and their co-morbidities, and the reality of patient preference providing subjective value to either modality

Study finds that individuals who took GLP-1 agonists for a long duration had a lower risk of going on to develop more severe forms of liver disease, including cirrhosis and liver cancer.

Todd Sohn, Strategas ETF & Technical Strategist, also joins the conversation.

Compared with DPP-4 inhibitors, the lower rate of hyperkalemia was consistently observed across individual agents in the SGLT-2 inhibitor (canagliflozin, dapagliflozin, empagliflozin) and GLP-1 receptor agonist (dulaglutide, exenatide, liraglutide, semaglutide) classes